Lieu, Christopher

The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection

Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H., & Boland, C. R. (2022) · The Lancet Gastroenterology & Hepatology

Colorectal Cancer Screening and DetectionGenetic factors in colorectal cancer

Cited by 812

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 682

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Baxter, N. N., Kennedy, E. B., Bergsland, E., Berlin, J., George, T. J., Gill, S., Gold, P. J., Hantel, A., Jones, L., Lieu, C., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 367

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research

Fibroblast Growth Factor ResearchAngiogenesis and VEGF in Cancer

Cited by 286

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 215

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 80

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

Kopetz, S., McDonough, S. L., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Raghav, K. P. S., Morris, V. K., Wang, S. E., et al. (2017) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 58

Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.

Lieu, C. H., Wolff, R. A., Eng, C., Overman, M. J., Henry, L., Coulson, R., Garrett, C. R., Abbruzzese, J. L., Gallick, G. E., & Kopetz, S. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 10

Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.

Lieu, C. H., Beeram, M., Harb, W. A., Kearns, J. D., Sloss, C. M., Nering, R., Adjei, A. A., & Wolf, B. B. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research

Cited by 7